HER-2-targeted therapy: lessons learned and future directions.
HER-2-targeted therapy: lessons learned and future directions.
复制标题
DOI：
--
复制
发表时间：
2003-11
期刊：
影响因子：
--
通讯作者：
R. Nahta;F. Esteva
中科院分区：
文献类型：
--
作者：
R. Nahta;F. Esteva
HER-2 在 20-25% 的浸润性乳腺癌中过度表达，与侵袭性肿瘤表型和生存率降低相关。肿瘤的 HER-2 状态是 HER-2 靶向抗体曲妥珠单抗反应的关键决定因素。因此，准确评估 HER-2 表达水平对于识别将从 HER-2 靶向治疗中受益的乳腺癌患者至关重要。曲妥珠单抗联合化疗可提高缓解率、进展时间和生存率。然而，大多数最初对曲妥珠单抗有反应的癌症在一年内开始再次进展。这篇小型综述描述了目前正在使用或处于开发阶段的乳腺癌治疗的 HER-2 靶向策略。
HER-2 is overexpressed in 20-25% of invasive breast cancers and is associated with an aggressive tumor phenotype and reduced survival rates. The HER-2 status of a tumor is the critical determinant of response to the HER-2-targeted antibody trastuzumab. Thus, accurate assessment of HER-2 expression levels is essential for identifying breast cancer patients who will benefit from HER-2-targeted therapy. Trastuzumab combined with chemotherapy increases response rates, time to progression, and survival. However, the majority of cancers that initially respond to trastuzumab begin to progress again within 1 year. This minireview describes HER-2 targeting strategies currently in use or in stages of development for the treatment of breast cancer.